Skip to main content

Scorpion Venom Tested as Brain Cancer Treatment

Scorpion Venom Tested as Brain Cancer Treatmen

A treatment based on scorpion venom loaded with radioactive material is being tested as a way to kill brain cancer.

If it is shown to work—and skepticism should prevail for now as testing is only in an early phase—the potion would simply be injected into a patient's bloodstream in an outpatient procedure.

About 17,000 U.S. residents suffer high-grade gliomas, a form of brain cancer that is usually fatal. A protein in venom from the yellow Israeli scorpion has been found to bind preferentially to the glioma cells, so scientists have created a synthetic version that does not by itself kill a patient.

In the bizarre treatment, when the venom protein attaches to the glioma cells, the radiation kills them.

The first, early human trials of the venom therapy "showed promising signs for treating tumors," scientists will report tomorrow at a meeting of the Health Physics Society meeting this week in Providence, Rhode Island. The research is being conducted by the Henry Ford Health System in Michigan and other institutions.

The work has not been published in a peer-reviewed journal, however, and initial trials have involved only a few dozen people.

Meanwhile, Richard Bucholz at the Saint Louis University School of Medicine is leading a separate clinical trial to test a similar product that combines scorpion venom with a different glioma-killing agent.

Bucholz's trial, however, involves inserting the drugs through catheters directly to the tumor sites in an effort to avoid possible side effects. Bucholz is also leading two other trials using "smart molecules" other than scorpion venom that are also designed to bind to glioma tumor cells and deliver lethal chemicals.

Today, Bucholz told LiveScience that a couple of patients "have seemingly had good responses," but he cautioned that it is too early to say how well the treatments might work.

“Malignant gliomas cannot be wholly eradicated through surgery or other currently available therapies,” Bucholz said. "A safe, effective treatment for malignant gliomas has the potential to increase the life expectancy of thousands of Americans suffering from this terrible disease."

Robert Roy Britt
Rob was a writer and editor at starting in 1999. He served as managing editor of Live Science at its launch in 2004. He is now Chief Content Officer overseeing media properties for the sites’ parent company, Purch. Prior to joining the company, Rob was an editor at The Star-Ledger in New Jersey, and in 1998 he was founder and editor of the science news website ExploreZone. He has a journalism degree from Humboldt State University in California.